Creation of the Biobank Related to Eye Disease (BioBank)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to develop a BioBank (a specialized lab) and collect blood, fluids and/or other tissue samples to study eye diseases.
| Condition |
|---|
|
Eye Diseases |
| Study Type: | Observational |
| Study Design: | Time Perspective: Prospective |
| Official Title: | Creation of the Biobank Related to Eye Disease |
- To build the platform for a novel application of translational research that links cutting edge molecular laboratory techniques to clinical outcome studies [ Time Frame: unknown ] [ Designated as safety issue: No ]Biobanks can be used for numberous discovery applications such as: identification and structural characterization of human genes, expression analysis, or discovery proteomics. Biological specimens, when coupled with standardized treatment and outcome data, will be essential resources for the identification, characterization and validation of biomarkers that are predictive of disease and treatment.
Biospecimen Retention: Samples With DNA
blood, urine other body fluids (i.e. vitreous)
| Estimated Enrollment: | 2000 |
| Study Start Date: | June 2009 |
| Estimated Study Completion Date: | June 2020 |
| Estimated Primary Completion Date: | June 2014 (Final data collection date for primary outcome measure) |
The purpose of the Biobank related to eye disease at Beaumont Hospital is to help connect specialties and Specialists with each other, outside traditional limits of hospital or laboratory departments. The specimens (blood, fluids, and/or tissue samples) that will be collected from men, women and children will assist the researchers in a variety of studies on human eye diseases.
Research utilizing these specimens will allow for an increased understanding of the etiology, disease process, and response to treatments for various eye diseases, and will provide opportunities to subsequently improve our management decisions. Furthermore, projects that cross over between subspecialties are sparse and that is a limiting factor for the development of research that takes a more comprehensive approach.
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
All pediatric and adult patients (age 0-99)who are being seen in the eye Dr. office and or having eye surgery
Inclusion Criteria: All pediatric and adult patients age 0-99 years -
Exclusion Criteria: All patients who do not agree to consent for collection of blood, fluids, tissue.
Patients who are cognitively impaired and are not able to verbalize understanding of the risks/benefits.
-
Contacts and Locations| Contact: Kimberly Drenser, MD, PhD | 248-288-2280 | kdrenser@arcpc.net |
| United States, Michigan | |
| William Beaumont Hospital | Recruiting |
| Royal Oak, Michigan, United States, 48073 | |
| Contact: Kimberly Drenser, MD, PhD 248-288-2280 | |
| Principal Investigator: | Kimberly Drenser, MD, PhD | Associated Retinal Consultants, P.C. |
More Information
No publications provided
| Responsible Party: | Kimberly Drenser, M.D, Ph.D., William Beaumont Hospitals |
| ClinicalTrials.gov Identifier: | NCT01240343 History of Changes |
| Other Study ID Numbers: | 2009-057 |
| Study First Received: | November 10, 2010 |
| Last Updated: | November 6, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by William Beaumont Hospitals:
|
Biobank Genetics |
Additional relevant MeSH terms:
|
Eye Diseases |
ClinicalTrials.gov processed this record on May 16, 2013